November is #PancreaticCancerAwarenessMonth. RenovoRx joins the pancreatic cancer community in highlighting this difficult-to-treat disease and the urgent need for new treatment options. We remain committed to advancing innovative, targeted approaches that may improve outcomes for patients with #PancreaticCancer. Learn about our work: https://t.co/v1hidYzGuR
#PancreaticCancer #LocallyAdvancedPancreaticCancer #CancerResearch #OncologyInnovation #TargetedTherapy #TAMP
Spectrum News shares a Moffitt Cancer Center patient story highlighting RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) platform, designed to deliver chemotherapy near solid tumors, such as pancreatic cancer, while minimizing systemic toxicity.
After extensive chemotherapy and radiation for locally advanced pancreatic cancer, Richard Martin received treatment via TAMP and returned to biking, fishing, and sharing meals with friends.
Richard’s experience reinforces our commitment to advancing drug-delivery options for difficult-to-treat tumors.
Learn more: https://t.co/aRa8uzbD6c
#PancreaticCancer #LocallyAdvancedPancreaticCancer #TAMP #Oncology
Disclaimer: The following content discusses our Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by our FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath-enabled TAMP with gemcitabine for the treatment of locally advanced pancreatic cancer (LAPC) is being studied under an IND. This combination product candidate has not been approved by FDA for commercial use and its safety and effectiveness in treating LAPC has not been established. For RenovoCath’s Indications for Use and safety information, please visit IFU-10004-Rev.-H-Universal-IFU.pdf
During #IOAwarenessWeek, RenovoRx is celebrating the patients, caregivers, physicians, researchers, and healthcare professionals who continue to advance understanding and awareness of IO. We’re proud to be part of a community working to make a meaningful difference in cancer care. Join us 26–30 October and help spread the word about IO. Share the Message. Raise Awareness. Learn more: https://t.co/V1gh9kz0G4
CEO Shaun Bagai spoke with MedTech Mentor's Crystal Howell about his MedTech journey, key lessons, and passion for innovative therapies that maximize patient impact.
He also highlights RenovoRx’s TAMP™ platform, enabled by the FDA-cleared RenovoCath® device, and its potential to reshape treatment for difficult-to-treat tumors like #pancreaticcancer.
Watch the full conversation: https://t.co/uHAbwAY3sz
“For patients with borderline resectable pancreatic cancer, treatment before surgery can influence both whether surgery is possible and how completely the tumor can be removed,” Conor O’Neill, MD, Assistant Professor at the @UVMLarnerMed, surgical oncologist at the UVM Medical Center, and principal investigator of PRISM-TAMP. Read more: https://t.co/jbCczzSVnh $RNXT
“Enrolling the first PRISM-TAMP patient marks an important step for our IIT program as it moves from concept to clinical execution,” said Leesa Gentry, Chief Clinical Officer of RenovoRx. PRISM-TAMP, sponsored by @uvmvermont, is the first RenovoRx supported IIT to advance to patient enrollment. Learn more: https://t.co/jbCczzSVnh $RNXT
RenovoRx announced the first patient has enrolled in PRISM-TAMP, an investigator-initiated trial sponsored by @uvmvermont. One week after the IIT began, a second patient is also progressing toward TAMP treatment.
PRISM-TAMP is evaluating the approved gemcitabine delivered via RenovoRx’s TAMP platform, enabled by RenovoCath®, as neoadjuvant treatment before surgery in patients with borderline PDAC. Learn more: https://t.co/jbCczzSVnh $RNXT
“This innovative approach to delivering cancer treatment not only has the potential to improve outcomes for our patients but also preserve their quality of life, which is our ultimate goal," shared Joe K. Khoury, DO, MBA, an interventional radiologist at @WinshipAtEmory and assistant professor in the Department of Radiology and Imaging Sciences at @EmoryMedicine. Read more: https://t.co/6gd6d78YBz
“Locally advanced pancreatic cancer remains one of the most difficult cancers to treat, and patients have limited options when standard systemic therapies, like intravenous chemotherapy, are no longer effective,” said @MdTiesi, MD, FACS, FSSO, Chief of Surgical Oncology for the Southern Region and Medical Director of Hepatobiliary Surgery at @HMHNewJersey University Medical Center and lead author of the case series. Read more: https://t.co/mja9t98cgd $RNXT
“Independent, peer-reviewed publications such as this case series provide important clinical evidence supporting the potential of our novel, targeted drug-delivery approach,” Dr. Agah, RenovoRx’s Chief Medical Officer, Executive Chairman, and Founder, comments on the recently published peer-reviewed case series in Case Reports in Oncology. Learn more: https://t.co/mja9t98cgd $RNXT
RenovoRx announced the publication of a peer-reviewed case series in Case Reports in Oncology from researchers at @HMHNewJersey University Medical Center. The case series reports tumor treatment response, significant tumor marker reduction, and changes on imaging after treatment with TAMP™ in patients with unresectable #LAPC. For more info: https://t.co/mja9t98cgd $RNXT
RenovoRx is pleased that institutions like @WinshipAtEmory and @emoryhealthcare are adopting RenovoRx's innovative, targeted drug-delivery approach for patients diagnosed with #LocallyAdvancedPancreaticCancer. The approach uses our patented Trans-Arterial Micro-Perfusion (TAMP™) platform, enabled by the RenovoCath® device.
TAMP delivers therapeutic agents near the tumor site, with the potential to reduce toxicities associated with systemic chemotherapy and improve patient outcome and quality of life. https://t.co/6gd6d78YBz
Reminder: CEO Shaun Bagai and CFO Mark Voll will present at the H.C. Wainwright 28th Annual Global Investment Conference today, September 14th at 1:30 pm ET. For webcast details, visit: https://t.co/Fob4zeaq1U
#HCWConference
A recent @OncLive article highlights pharmacokinetic and pharmacodynamic (PK-PD) data from a sub-study of RenovoRx's Phase III TIGeR-PaC trial, published in Cancer Chemotherapy and Pharmacology. In patients with locally advanced pancreatic cancer, gemcitabine delivered via our Trans-Arterial Micro-Perfusion (TAMP™) platform using the RenovoCath® device, resulted in approximately 51% drug extraction at the tumor site before systemic circulation. Compared with standard intravenous delivery, TAMP also reduced systemic exposure and showed a significant correlation between drug metabolite levels and reductions in tumor markers, despite higher infusion-phase concentrations.
Read the full article: https://t.co/MfM0b4RboW
RenovoRx CEO Shaun Bagai and CFO Mark Voll will present at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14 at 1:30 p.m. ET. They will discuss record second quarter revenue, driven by increasing commercial demand for RenovoCath® as a standalone drug-delivery device and strong repeat orders from high-volume cancer centers. Shaun will also share an update on the fully enrolled Phase III TIGeR-PaC trial, which is expected to conclude in the first half of 2027, with initial topline data anticipated in the second half of 2027. For details:: https://t.co/zH0FUTvWB0
$RNXT #HCWConference
“The findings from this PK/PD study provide additional meaningful mechanistic support for our TAMP™ platform’s targeted drug-delivery approach,” said Ramtin Agah, M.D., Executive Chairman, Chief Medical Officer, and Founder of RenovoRx. Learn about the PK/PD data from a sub-study of the ongoing Phase III TIGeR-PaC clinical trial published in the journal Cancer Chemotherapy and Pharmacology: https://t.co/LJ4W5t4F8I $RNXT
RenovoRx announced the publication of PK/PD data from a sub-study of its ongoing Phase III TIGeR-PaC trial (NCT03257033) in Cancer Chemotherapy and Pharmacology. The study showed an approximately 51% tumor-site drug extraction, decreased systemic exposure, and a significant correlation between drug metabolite levels and tumor marker reduction, supporting the targeted drug-delivery approach of RenovoRx’s proprietary TAMP™ platform in locally advanced pancreatic cancer (LAPC). https://t.co/LJ4W5t4F8I $RNXT
"Patients getting chemotherapy through this catheter are really experiencing a lot less chemotherapy-related toxicity," says Dr. Kelsey Klute of @BuffettCancer, in a new @Channel8ABC feature on RenovoRx's RenovoCath® device now in clinical use at UNMC.
Watch: https://t.co/Bxam7Qhe8a
RenovoCath is FDA-cleared for targeted delivery of chemotherapy to selected sites in the peripheral vascular system. The company is studying the use of RenovoCath-delivered gemcitabine for treatment of LAPC in an ongoing clinical trial conducted under an IND.
#PancreaticCancer #TargetedTherapy
RenovoRx announced that it has received written notification from The Nasdaq Stock Market LLC confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. For more info: https://t.co/EwJwBpm0ND $RNXT
RenovoRx's recently issued notice of allowance from the U.S. Patent and Trademark Office strengthens RenovoRx’s expanding intellectual property portfolio and provides additional patent protection for RenovoCath®, an advanced dual-occlusion catheter, designed to deliver cancer therapies directly to targeted tumor sites, further supporting the Company’s commercialization strategy in precision oncology. https://t.co/nM19BOcuCb $RNXT